This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral
Andreas Harstrick, MD
Advertisement
Articles by Andreas Harstrick, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Anticipated Data and Practice-Changing Trials: An ASCO 2026 Breast Cancer Preview
2
FDA Approves Pivekimab Sunirine in Rare Hematologic Malignancy
3
Concomitant COVID-19 Vaccination Tied to Improved OS With Immunotherapy
4
FDA Approves FoundationOne CDx for Tepotinib in MET+ NSCLC
5